Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2017 > Volume 26 Number 6 November 2017 > DEVICE EVALUATION > Early Experience with the Latest-Generation Biological Prosthesis, the Trifecta™ GT

Early Experience with the Latest-Generation Biological Prosthesis, the Trifecta™ GT

Federico Paredes1,5, Arnaldo Estigarribia Bernal1, Eduard Permanyer1, Javier Poncela2, Alejandro Ysasi3, Enrique Herrero3, Manuel Maynar4, Rafael Llorens1

1Cardiac Surgery Department, Hospiten Rambla, Santa Cruz de Tenerife, Spain
2Cardiology Department, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Spain
3Anesthesiology Department, Hospiten Rambla. Santa Cruz de Tenerife, Spain
4Las Palmas de Gran Canaria University, Palma de Gran Canaria, Spain
5Electronic correspondence: feco_py@hotmail.com

Background and aim of the study: The study aim was to assess the hemodynamic results and implantation technique for the latest-generation St. Jude Medical aortic valve bioprosthesis, the Trifecta™ GT, which was first marketed in 2016.

Methods: The first 100 patients (mean age 74.59 ± 7.41 years) undergoing aortic valve replacement (AVR) with the Trifecta GT, whether associated or not

with other procedures, were included and assessed. All patients underwent a baseline ultrasound scan prior to hospital discharge to monitor postoperative gradients and the presence of periprosthetic leakage.

Results: The predominant valvular heart disease was aortic stenosis (85%). An isolated AVR was required

 

in 43% of patients. The prosthesis sizes used were 19, 21, 23, 25, and 27 mm. The overall hospital mortality was 5%; all deaths occurred in patients with associated surgeries. Peak gradients measured prior to hospital discharge ranged from 17.95 mmHg to 10.95 mmHg for 19 mm and 27 mm prostheses, respectively; mean gradients were 9.94 and 6.18 mmHg for 19 mm and 27 mm prostheses, respectively. Neither implant-related complications nor significant periprosthetic leakages were recorded.

Conclusion: Based on experience with patients, the Trifecta GT demonstrated an excellent hemodynamic performance after implantation, which involved a simple and safe technique. Further long-term studies to determine the durability of the prosthesis are required.

The Journal of Heart Valve Disease 2017;26:721-727


Early Experience with the Latest-Generation Biological Prosthesis, the Trifecta™ GT

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.